Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropat...

Descripción completa

Detalles Bibliográficos
Autores principales: Dardari, Dured, Thomas, Claire, Laborne, Francois-Xavier, Tourte, Caroline, Henry, Elodie, Erblang, Megane, Bourdon, Stéphanie, Penfornis, Alfred, Lopes, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029471/
https://www.ncbi.nlm.nih.gov/pubmed/35454393
http://dx.doi.org/10.3390/medicina58040555
_version_ 1784691886350401536
author Dardari, Dured
Thomas, Claire
Laborne, Francois-Xavier
Tourte, Caroline
Henry, Elodie
Erblang, Megane
Bourdon, Stéphanie
Penfornis, Alfred
Lopes, Philippe
author_facet Dardari, Dured
Thomas, Claire
Laborne, Francois-Xavier
Tourte, Caroline
Henry, Elodie
Erblang, Megane
Bourdon, Stéphanie
Penfornis, Alfred
Lopes, Philippe
author_sort Dardari, Dured
collection PubMed
description The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.
format Online
Article
Text
id pubmed-9029471
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90294712022-04-23 Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study Dardari, Dured Thomas, Claire Laborne, Francois-Xavier Tourte, Caroline Henry, Elodie Erblang, Megane Bourdon, Stéphanie Penfornis, Alfred Lopes, Philippe Medicina (Kaunas) Study Protocol The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023. MDPI 2022-04-18 /pmc/articles/PMC9029471/ /pubmed/35454393 http://dx.doi.org/10.3390/medicina58040555 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Study Protocol
Dardari, Dured
Thomas, Claire
Laborne, Francois-Xavier
Tourte, Caroline
Henry, Elodie
Erblang, Megane
Bourdon, Stéphanie
Penfornis, Alfred
Lopes, Philippe
Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title_full Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title_fullStr Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title_full_unstemmed Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title_short Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
title_sort impact of the rapid normalization of chronic hyperglycemia on the receptor activator of nuclear factor-kappa b ligand and the osteoprotegerin system in patients living with type 2 diabetes: rankl-glyc study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029471/
https://www.ncbi.nlm.nih.gov/pubmed/35454393
http://dx.doi.org/10.3390/medicina58040555
work_keys_str_mv AT dardaridured impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT thomasclaire impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT labornefrancoisxavier impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT tourtecaroline impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT henryelodie impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT erblangmegane impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT bourdonstephanie impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT penfornisalfred impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy
AT lopesphilippe impactoftherapidnormalizationofchronichyperglycemiaonthereceptoractivatorofnuclearfactorkappabligandandtheosteoprotegerinsysteminpatientslivingwithtype2diabetesranklglycstudy

Ejemplares similares